Samuel & thread
Mr. Wexler's comments on TXB reflect what seems to be a particular dislike for Texas based companies [maybe just the ones on my profile ;-)].
A month or two ago he showed up on the TXB thread but quickly left with his tail between his legs. I guess if Asholio isn't making the kill this vulture can't find food (for thought?).
FWIW - TXB has filed an NDA and been granted expedited review for a new anticoagulant (Novastan) for patients that have developed an allergy to heparin causing a condition called heparin induced thrombocytopenia. FDA decision is expected in the 2nd quarter. They also have a FULL product pipeline in various stages of clinical and pre-clinical trials.
Just thought everyone might like to see the gang of thieves & villains that make up the TXB Board of Directors.
John M. Pietruski
Chairman of the Board,
Retired Chairman and Chief Executive Officer,
Sterling Drug Inc.
David B. McWilliams
President and Chief Executive Officer
Rita R. Colwell, Ph.D.
President, University of Maryland
Biotechnology Institute
Frank C. Carlucci
Chairman,The Carlyle Group
Robert J. Cruikshank
Retired Senior Partner, Deloitte Touche LL
James A. Thomson, Ph.D.
President and Chief Executive Officer,
RAND Corporation
James T. Willerson, M.D.
Professor and Chairman, Department of Internal Medicine
The University of Texas Medical School
============================================================
Oh, and before I forget, the Advisory Director to the Company is:
Denton A. Cooley, M.D.
Surgeon-in-Chief,
The Texas Heart Institute
Ever hear of him?? Some people consider him the most influential physician of THIS CENTURY (please, no arguments here - this is not the point). However, to Mr. Wexler, Dr. Cooley is well known by the investment community to seek out fraudulent companies as he desperately needs some extra spending cash.
OH, one more thing, Carlucci once held a small job - Sec'y. of Defense |
